http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002520287-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
filingDate 1999-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2002-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2002520287-A
titleOfInvention Prophylactic treatment of angiogenesis in macular degeneration
abstract (57) Abstract The present invention relates to the prevention of choroidal neovascularization in macular degeneration by introducing a suitable anti-inflammatory agent into the vitreous. In particular, this is the prevention of angiogenesis by anti-inflammatory steroids, such as 11-substituted 16α, 17α-substituted methylenedioxysteroids of formula (I), in eyes identified as having an increased risk of developing choroidal neovascularization. Where (a) is (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), R 1 and R 2 are hydrogen or alkyl; -C a -C b -is -CH 2 -CH 2- , -CH = CH-, (m), or (n) There; R 3 is methyl, hydroxymethyl or alkylcarbonyloxy methyl, is methyl aminoalkylene carbonyloxy methyl or phenyl aminoalkylene carbonyloxy methyl,; R 4 is an alkanoyl; and X is halogen. More specifically, this relates to prophylaxis with triamcinolone acetonide (Compound II). Embedded image (I) (II) (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l) (m) (n)
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007520496-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005072744-A1
priorityDate 1998-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID410087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533589
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420033637
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5426
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577181
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546247
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6436
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501808
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22796701
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6215
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID247929
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505112
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448241444
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397482
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31307

Total number of triples: 34.